{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:37:49Z","timestamp":1769517469314,"version":"3.49.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"crossref"}]},{"name":"South African National Research Foundation","award":["118022 and 120383"],"award-info":[{"award-number":["118022 and 120383"]}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Female Academic Leadership Fund"},{"name":"Carnegie\/WITS University Enabling grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02662-5","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:26:11Z","timestamp":1739838371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector"],"prefix":"10.1186","volume":"22","author":[{"given":"Njabulo Ziphezinhle","family":"Mnyandu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shonisani Wendy","family":"Limani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Ely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reubina","family":"Wadee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohube Betty","family":"Maepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2662_CR1","unstructured":"WHO. Interim guidance for country validation of viral hepatitis elimination. WHO; 2021."},{"key":"2662_CR2","doi-asserted-by":"crossref","unstructured":"Ogunnaike M et al. Chronic Hepatitis B infection: New approaches towards Cure. Biomolecules, 2023. 13(8).","DOI":"10.3390\/biom13081208"},{"issue":"1","key":"2662_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","volume":"75","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001;75(1):311\u201322.","journal-title":"J Virol"},{"issue":"12","key":"2662_CR4","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1128\/JVI.76.12.6356-6363.2002","volume":"76","author":"WR Addison","year":"2002","unstructured":"Addison WR, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol. 2002;76(12):6356\u201363.","journal-title":"J Virol"},{"issue":"1","key":"2662_CR5","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.aohep.2024.101533","volume":"30","author":"PG Naully","year":"2024","unstructured":"Naully PG, et al. cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B. Ann Hepatol. 2024;30(1):101533.","journal-title":"Ann Hepatol"},{"issue":"6037","key":"2662_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/317489a0","volume":"317","author":"P Tiollais","year":"1985","unstructured":"Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985;317(6037):489\u201395.","journal-title":"Nature"},{"issue":"7594","key":"2662_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature17170","volume":"531","author":"A Decorsiere","year":"2016","unstructured":"Decorsiere A, et al. Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor. Nature. 2016;531(7594):386\u20139.","journal-title":"Nature"},{"issue":"1","key":"2662_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1568010043483908","volume":"3","author":"K Hanazaki","year":"2004","unstructured":"Hanazaki K. Antiviral therapy for chronic hepatitis B: a review. Curr Drug Targets Inflamm Allergy. 2004;3(1):63\u201370.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"2","key":"2662_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0166-3542(01)00178-4","volume":"52","author":"AB van Nunen","year":"2001","unstructured":"van Nunen AB, et al. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res. 2001;52(2):139\u201346.","journal-title":"Antiviral Res"},{"issue":"4","key":"2662_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/17843286.2022.2152566","volume":"78","author":"Y Davidov","year":"2023","unstructured":"Davidov Y, et al. Real-world hepatitis B antiviral treatment trends and adherence to practice guidelines: a large cohort study. Acta Clin Belg. 2023;78(4):291\u20137.","journal-title":"Acta Clin Belg"},{"key":"2662_CR11","doi-asserted-by":"publisher","first-page":"1322892","DOI":"10.3389\/fmicb.2023.1322892","volume":"14","author":"F Wang","year":"2023","unstructured":"Wang F, et al. Role of hepatitis B virus non-structural protein HBx on HBV replication, interferon signaling, and hepatocarcinogenesis. Front Microbiol. 2023;14:1322892.","journal-title":"Front Microbiol"},{"issue":"1","key":"2662_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2021.08.010","volume":"76","author":"K Sekiba","year":"2022","unstructured":"Sekiba K, et al. HBx-induced degradation of Smc5\/6 complex impairs homologous recombination-mediated repair of damaged DNA. J Hepatol. 2022;76(1):53\u201362.","journal-title":"J Hepatol"},{"key":"2662_CR13","doi-asserted-by":"crossref","unstructured":"Li D, Hamadalnil Y, Tu T. Hepatitis B viral protein HBx: roles in viral replication and Hepatocarcinogenesis. Viruses, 2024. 16(9).","DOI":"10.3390\/v16091361"},{"issue":"3","key":"2662_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1021\/mp800157x","volume":"6","author":"S Carmona","year":"2009","unstructured":"Carmona S, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009;6(3):706\u201317.","journal-title":"Mol Pharm"},{"issue":"4","key":"2662_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.bmc.2011.12.024","volume":"20","author":"J Brzezinska","year":"2012","unstructured":"Brzezinska J, et al. Synthesis of 2\u2019-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem. 2012;20(4):1594\u2013606.","journal-title":"Bioorg Med Chem"},{"key":"2662_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2015.04.042","volume":"209","author":"MD Marimani","year":"2015","unstructured":"Marimani MD, et al. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015;209:198\u2013206.","journal-title":"J Control Release"},{"key":"2662_CR17","doi-asserted-by":"crossref","unstructured":"Yuen MF et al. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut. 2022;71(4):789\u201397.","DOI":"10.1136\/gutjnl-2020-323445"},{"key":"2662_CR18","doi-asserted-by":"crossref","unstructured":"Mak LY et al. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 2025;74:440\u201350.","DOI":"10.1136\/gutjnl-2024-333026"},{"key":"2662_CR19","doi-asserted-by":"crossref","unstructured":"Cideciyan AV et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. 2008(1091\u20136490 (Electronic)).","DOI":"10.1073\/pnas.0807027105"},{"issue":"4","key":"2662_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1089\/hum.2018.007","volume":"29","author":"U Kassner","year":"2018","unstructured":"Kassner U, et al. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the first patient treated with Alipogene Tiparvovec under Daily Practice conditions. Hum Gene Ther. 2018;29(4):520\u20137.","journal-title":"Hum Gene Ther"},{"issue":"26","key":"2662_CR21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, et al. AAV5-Factor VIII gene transfer in severe Hemophilia A. N Engl J Med. 2017;377(26):2519\u201330.","journal-title":"N Engl J Med"},{"key":"2662_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.omtn.2017.04.007","volume":"7","author":"MB Maepa","year":"2017","unstructured":"Maepa MB, et al. Sustained inhibition of HBV Replication in Vivo after systemic injection of AAVs encoding Artificial Antiviral Primary MicroRNAs. Mol Ther Nucleic Acids. 2017;7:190\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"2662_CR23","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.15252\/emmm.201506172","volume":"8","author":"T Michler","year":"2016","unstructured":"Michler T, et al. Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol Med. 2016;8(9):1082\u201398.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"2662_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","volume":"12","author":"E Zinn","year":"2015","unstructured":"Zinn E, et al. Silico Reconstruction of the viral evolutionary lineage yields a potent gene therapy Vector. Cell Rep. 2015;12(6):1056\u201368.","journal-title":"Cell Rep"},{"key":"2662_CR25","volume-title":"Successful disabling of the 5\u2019 UTR of HCV using adeno-associated viral vectors to deliver artificial primary microrna mimics","author":"T Bourhill","year":"2015","unstructured":"Bourhill T. Successful disabling of the 5\u2019 UTR of HCV using adeno-associated viral vectors to deliver artificial primary microrna mimics. University of the Witwatersrand: South Africa; 2015."},{"issue":"7","key":"2662_CR26","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1128\/jvi.66.7.4107-4116.1992","volume":"66","author":"M Nassal","year":"1992","unstructured":"Nassal M. The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J Virol. 1992;66(7):4107\u201316.","journal-title":"J Virol"},{"issue":"3","key":"2662_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/sj.mt.6300077","volume":"15","author":"MS Weinberg","year":"2007","unstructured":"Weinberg MS, et al. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007;15(3):534\u201341.","journal-title":"Mol Ther"},{"key":"2662_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-0716-0290-4_10","volume":"2115","author":"N Mnyandu","year":"2020","unstructured":"Mnyandu N, Arbuthnot P, Maepa MB. Vivo delivery of cassettes encoding Anti-HBV primary MicroRNAs using an ancestral Adeno-Associated viral vector. Methods Mol Biol. 2020;2115:171\u201383.","journal-title":"Methods Mol Biol"},{"issue":"16","key":"2662_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","volume":"8","author":"DM McCarty","year":"2001","unstructured":"McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248\u201354.","journal-title":"Gene Ther"},{"issue":"1","key":"2662_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1128\/JVI.80.1.426-439.2006","volume":"80","author":"D Grimm","year":"2006","unstructured":"Grimm D, et al. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol. 2006;80(1):426\u201339.","journal-title":"J Virol"},{"issue":"3","key":"2662_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","volume":"443","author":"M Iwamoto","year":"2014","unstructured":"Iwamoto M, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 2014;443(3):808\u201313.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"2662_CR32","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1093\/nar\/gkp446","volume":"37","author":"A Ely","year":"2009","unstructured":"Ely A, Naidoo T, Arbuthnot P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009;37(13):e91.","journal-title":"Nucleic Acids Res"},{"key":"2662_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-4939-3112-5_20","volume":"1364","author":"C Crowther","year":"2016","unstructured":"Crowther C, Mowa B, Arbuthnot P. Hepatic delivery of Artificial Micro RNAs using helper-dependent adenoviral vectors. Methods Mol Biol. 2016;1364:249\u201360.","journal-title":"Methods Mol Biol"},{"key":"2662_CR34","first-page":"197","volume-title":"A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus. Frontieviral Viral Hepatitis","year":"2003","unstructured":"Schinazi RF, Sommadossi JP, Rice CM, editors. A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus. Frontieviral Viral Hepatitis. Amsterdam, The Netherlands: Elsevier Science; 2003. pp. 197\u2013202."},{"issue":"7","key":"2662_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods"},{"key":"2662_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1743-422X-10-74","volume":"10","author":"BL Ellis","year":"2013","unstructured":"Ellis BL, et al. A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J. 2013;10:74.","journal-title":"Virol J"},{"issue":"9\u201310","key":"2662_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/hum.2019.264","volume":"31","author":"A Westhaus","year":"2020","unstructured":"Westhaus A, et al. High-throughput in Vitro, Ex vivo, and in vivo screen of Adeno-Associated Virus vectors based on physical and functional transduction. Hum Gene Ther. 2020;31(9\u201310):575\u201389.","journal-title":"Hum Gene Ther"},{"key":"2662_CR38","doi-asserted-by":"publisher","first-page":"p718743","DOI":"10.1155\/2014\/718743","volume":"2014","author":"MB Mowa","year":"2014","unstructured":"Mowa MB, et al. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-mirs from a liver-specific promoter. Biomed Res Int. 2014;2014:p718743.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2662_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cid\/ciy1100","volume":"69","author":"R Loomba","year":"2019","unstructured":"Loomba R, et al. Discovery of Half-life of circulating Hepatitis B Surface Antigen in patients with chronic Hepatitis B infection using Heavy Water labeling. Clin Infect Dis. 2019;69(3):542\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2662_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hep.21364","volume":"44","author":"JM Murray","year":"2006","unstructured":"Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virions. Hepatology. 2006;44(5):1117\u201321.","journal-title":"Hepatology"},{"issue":"3","key":"2662_CR41","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/jcmm.13444","volume":"22","author":"M Huang","year":"2018","unstructured":"Huang M, et al. Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy. J Cell Mol Med. 2018;22(3):1675\u201383.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2662_CR42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/mt.2008.82","volume":"16","author":"A Ely","year":"2008","unstructured":"Ely A, et al. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008;16(6):1105\u201312.","journal-title":"Mol Ther"},{"issue":"2","key":"2662_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/gt.2014.94","volume":"22","author":"D Ivacik","year":"2015","unstructured":"Ivacik D, et al. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015;22(2):163\u201371.","journal-title":"Gene Ther"},{"issue":"10","key":"2662_CR44","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3389","volume":"47","author":"JC Nault","year":"2015","unstructured":"Nault JC, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47(10):1187\u201393.","journal-title":"Nat Genet"},{"issue":"2","key":"2662_CR45","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler RJ, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Investig. 2015;125(2):870\u201380.","journal-title":"J Clin Investig"},{"issue":"8","key":"2662_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3893","volume":"49","author":"GJ Logan","year":"2017","unstructured":"Logan GJ, et al. Identification of liver-specific enhancer-promoter activity in the 3\u2019 untranslated region of the wild-type AAV2 genome. Nat Genet. 2017;49(8):1267\u201373.","journal-title":"Nat Genet"},{"key":"2662_CR47","unstructured":"- SRF, Chang LS, Chang Ls T, Fau, Shenk, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. 1987(0022-538X (Print))."},{"issue":"1","key":"2662_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/JVI.73.1.161-169.1999","volume":"73","author":"D Duan","year":"1999","unstructured":"Duan D, et al. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol. 1999;73(1):161\u20139.","journal-title":"J Virol"},{"issue":"11","key":"2662_CR49","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","volume":"72","author":"D Duan","year":"1998","unstructured":"Duan D, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72(11):8568\u201377.","journal-title":"J Virol"},{"issue":"11","key":"2662_CR50","doi-asserted-by":"publisher","first-page":"9468","DOI":"10.1128\/JVI.73.11.9468-9477.1999","volume":"73","author":"J Yang","year":"1999","unstructured":"Yang J, et al. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol. 1999;73(11):9468\u201377.","journal-title":"J Virol"},{"issue":"5","key":"2662_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"2662_CR52","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"1","key":"2662_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","volume":"39","author":"GN Nguyen","year":"2021","unstructured":"Nguyen GN, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47\u201355.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2662_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, et al. Severe toxicity in Nonhuman Primates and piglets following high-dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther. 2018;29(3):285\u201398.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2662_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3851\/IMP2713","volume":"19","author":"C Crowther","year":"2014","unstructured":"Crowther C, et al. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014;19(4):363\u201373.","journal-title":"Antivir Ther"},{"issue":"1","key":"2662_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","volume":"32","author":"SS Iyer","year":"2012","unstructured":"Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23\u201363.","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"2662_CR57","first-page":"37","volume":"15","author":"M Hacham","year":"2004","unstructured":"Hacham M, et al. Interleukin-6 and interleukin-10 are expressed in organs of normal young and old mice. Eur Cytokine Netw. 2004;15(1):37\u201346.","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"2662_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2567.2008.02986.x","volume":"127","author":"Y Yanagawa","year":"2009","unstructured":"Yanagawa Y, Iwabuchi K, Ono\u00e9 K. Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell functions. Immunology. 2009;127(3):345\u201353.","journal-title":"Immunology"},{"issue":"9","key":"2662_CR59","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2008.144","volume":"16","author":"JC Giering","year":"2008","unstructured":"Giering JC, et al. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther. 2008;16(9):1630\u20136.","journal-title":"Mol Ther"},{"issue":"7092","key":"2662_CR60","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature04791","volume":"441","author":"D Grimm","year":"2006","unstructured":"Grimm D, et al. Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways. Nature. 2006;441(7092):537\u201341.","journal-title":"Nature"},{"issue":"9","key":"2662_CR61","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1172\/JCI43565","volume":"120","author":"D Grimm","year":"2010","unstructured":"Grimm D, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest. 2010;120(9):3106\u201319.","journal-title":"J Clin Invest"},{"key":"2662_CR62","doi-asserted-by":"crossref","unstructured":"Boudreau RL, Martins I, Davidson BL. Artificial MicroRNAs as siRNA shuttles: Improved Safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2008;17(1):169\u201375.","DOI":"10.1038\/mt.2008.231"},{"issue":"2","key":"2662_CR63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34(2):204\u20139.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2662_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","volume":"26","author":"NK Paulk","year":"2018","unstructured":"Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver transduction in vivo and Unique Humoral Seroreactivity. Mol Ther. 2018;26(1):289\u2013303.","journal-title":"Mol Ther"},{"issue":"22","key":"2662_CR65","doi-asserted-by":"publisher","first-page":"e131610","DOI":"10.1172\/jci.insight.131610","volume":"4","author":"K Pekrun","year":"2019","unstructured":"Pekrun K, et al. Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight. 2019;4(22):e131610.","journal-title":"JCI Insight"},{"issue":"24","key":"2662_CR66","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","volume":"114","author":"LV Tse","year":"2017","unstructured":"Tse LV, et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A. 2017;114(24):E4812\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2662_CR67","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/hep.26990","volume":"59","author":"M Hosel","year":"2014","unstructured":"Hosel M, et al. Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo. Hepatology. 2014;59(6):2110\u201320.","journal-title":"Hepatology"},{"issue":"10","key":"2662_CR68","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1128\/jvi.69.10.6158-6169.1995","volume":"69","author":"LG Guidotti","year":"1995","unstructured":"Guidotti LG, et al. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995;69(10):6158\u201369.","journal-title":"J Virol"},{"key":"2662_CR69","doi-asserted-by":"crossref","unstructured":"Ko C et al. Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors. Antiviral Res. 2021;194:105140.","DOI":"10.1016\/j.antiviral.2021.105140"},{"key":"2662_CR70","doi-asserted-by":"crossref","unstructured":"Limani SW et al. In vivo modelling of Hepatitis B Virus Subgenotype A1 Replication using Adeno-Associated viral vectors. Viruses, 2021. 13(11).","DOI":"10.3390\/v13112247"},{"key":"2662_CR71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.antiviral.2017.07.006","volume":"145","author":"J Lucifora","year":"2017","unstructured":"Lucifora J, et al. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Res. 2017;145:14\u20139.","journal-title":"Antiviral Res"},{"key":"2662_CR72","doi-asserted-by":"crossref","unstructured":"Ye L et al. Adeno-Associated Virus Vector mediated delivery of the HBV Genome induces chronic Hepatitis B Virus infection and liver fibrosis in mice. PLoS ONE, 2015. 10(6).","DOI":"10.1371\/journal.pone.0130052"},{"key":"2662_CR73","doi-asserted-by":"crossref","unstructured":"van den Berg F et al. Advances with RNAi-Based therapy for Hepatitis B Virus infection. Viruses, 2020. 12(8).","DOI":"10.3390\/v12080851"},{"issue":"1","key":"2662_CR74","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","volume":"9","author":"W Zai","year":"2024","unstructured":"Zai W, et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther. 2024;9(1):150.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2662_CR75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.gtc.2019.02.005","volume":"48","author":"KI Berns","year":"2019","unstructured":"Berns KI, Srivastava A. Next Generation of Adeno-Associated Virus vectors for Gene Therapy for Human Liver diseases. Gastroenterol Clin North Am. 2019;48(2):319\u201330.","journal-title":"Gastroenterol Clin North Am"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02662-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T09:14:04Z","timestamp":1743930844000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02662-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2662"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02662-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of HBV transgenic mice followed a protocol authorized by University of the Witwatersrand Animal Research and Ethics Committee (#2018\/11\/57\/B, date of approval: 21\/11\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}